SOFOSBUVIR RIBAVIRIN COMBINATION THERAPY RESPONSE IN CHRONIC HCV PATIENTS IN KHYBER PAKHTUNKHWA

Main Article Content

Jehanzeb Afridi
Nourin Mahmood
Sajid Ali
Bashir Ahmad
Fazal Jalil
Rahim Sher

Abstract

Objectives: To see the Sofosbuvir Ribavirin combination therapy response in chronic HCV patients.
Material and Methods: This study was conducted in private setup of Hepatitis clinics in collaboration with a private
clinical laboratory of Peshawar,Pakistan. The patients were enrolled from July 2016 to December 2017.A total of 65
patients (54 naïve and 11 non- responder/relapser) were enrolled in this study. Age range was 18- 70 years while mean
age was 36 ± 2 years. For all of the subjects’ biochemical profile and PCR tests were done at the start and end of
therapy. All patients were given Direct acting antiviral drugs (DAA) drug for six months and after six month of therapy
end of treatment response (ETR) was noted.
Results: All the enrolled patients achieved 100% ETR. Alanine amino transferase (ALT) level improved in most of the
patients (81%) while there was reduction in Hemoglobin level in 46.5% of the patients.
Conclusions: Response rate in the current study is much higher as compared to previous studies conducted on
Interferon based ribavairin therapy.

Article Details

How to Cite
AfridiJ., MahmoodN., AliS., AhmadB., JalilF., & SherR. (2018). SOFOSBUVIR RIBAVIRIN COMBINATION THERAPY RESPONSE IN CHRONIC HCV PATIENTS IN KHYBER PAKHTUNKHWA. Journal Of Medical Sciences, 26(3), 246-249. Retrieved from https://jmedsci.com/index.php/Jmedsci/article/view/582
Section
Articles